Table 3.

Relations of Achieving Target SU Level (<0.36 mmol/L) and Allopurinol Dose Escalation to All-Cause Mortality in Allopurinol Initiators With Gout and CKD in the Target Trial Emulation Studies

Variable	Achieving Target SU Level /Not Achieving Target SU Level	Dose Escalation/ No Dose Escalation
Patients, n	5277/5277	3696/3696
Weighted deaths, n	660/754	483/518
Weighted risk over 5 y, %	13.2/14.8	13.9/15.2
Inverse probability weighting risk difference, % (95% CI)	−1.6 (−3.6 to −0.5)	−1.4 (−3.7 to 0.4)
Inverse probability weighting hazard ratio (95% CI)	0.87 (0.75 to 1.01)	0.88 (0.73 to 1.07)

CKD = chronic kidney disease; SU = serum urate.